A T Cell-based HIV Vaccine
Study Details
Study Description
Brief Summary
The purpose of this research study is to develop a vaccine against Human immunodeficiency virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood from humans who have been exposed to HIV will be tested to see if the immune system will recognize the HIV and prevent infection.
HIV targets the immune system by attacking certain T cells called CD4+ T cells. There are parts on the AIDS viruses that help the virus infect these cells and other parts that help the immune system prevent viral infection by activating protective T-cells that fight HIV. Different T-cell populations are very important in most vaccines as they act as "effectors" that work as part of the immune system to recognize and fight off HIV infection. When effector T cells are activated by appropriate "protective" part(s) of the virus they either block HIV from reproducing or kill HIV infected cells. By finding these common protective parts of each of these human and animal AIDS viruses, the investigator hopes to make a vaccine that helps the immune system prevent HIV infection by avoiding parts that attack CD4+ T cells and may worsen HIV infection and selecting for parts that stimulate effector T cells that fight HIV infection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
As a participant in this study a blood drawn will performed.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| HIV positive subjects This group will provide a blood sample. |
Other: HIV positive subjects
This group will provide a blood sample.
|
| Non-infected control subjects This group consist of de-identified blood samples from a commercial source. |
Other: Non-infected control subjects
This group will be de-identified blood samples from a commercial source.
|
Outcome Measures
Primary Outcome Measures
- T cell proliferation in response to viral epitopes [120 hours (5 days)]
Secondary Outcome Measures
- Cytokine production in response to viral epitopes [24 hours (1 day)]
- Cytotoxin production in response to viral epitopes [8 hours]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Male and female subjects between 18 and 65 years old who are HIV positive
Exclusion Criteria:
- Persons with other immune diseases that would result in autoimmunity or aberrant immune responses (such as subjects who have undergone chemotherapy within the past year).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Florida | Gainesville | Florida | United States | 32611 |
| 2 | UF Center for AIDS Research Education and Service | Jacksonville | Florida | United States | 32209 |
Sponsors and Collaborators
- University of Florida
- Janet K. Yamamoto Donor Fund
- National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
- Principal Investigator: Janet K Yamamoto, PhD, University of Florida
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB201401012-N
- 5R01AI030904